*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Yet another experimental drug heavily touted by Pfizer Inc. has foundered in advanced testing, raising worries about productivity ...

A pill to treat obesity caused liver injury in a clinical trial Pfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity drugs are in ...

NEW YORK - Pfizer has started testing a booster shot of its COVID-19 vaccine in combination with a pneumococcal vaccine candidate, the company announced this week. The company has enrolled 600 fully ...

A Pfizer drug designed to address a severe problem associated with sickle cell disease failed to beat a placebo in a Phase 3 clinical trial. It’s the latest setback for Pfizer in this inherited blood ...

The pharma company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry leader.

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other ...

Pfizer said Friday it is halting the testing of a twice-daily obesity drug, citing side effects. The company said in a press release it will now focus its future efforts for the drug, danuglipron, on ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

See more Winnipeg Sun on Google - save as a Preferred Source ...

Texas Attorney General Ken Paxton has sued Pfizer and its drug manufacturer for allegedly providing medicine it knew to be ineffective. In a lawsuit unsealed Monday, Paxton sued Pfizer, Inc., Tris ...

Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The company said the injury went away after the person ...